Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer

PURPOSE: Molecular targeting is a powerful approach for aggressive claudin-low breast cancer (CLBC). Overexpression of PI3K catalytic subunit gamma (PIK3CG) in human CLBC is offering a promising opportunity for targeted therapies. We utilized a specific inhibitor of PIK3CG combined with paclitaxel (...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Manag Res
Hlavní autoři: Chang, Jun, Hong, Ling, Liu, Yaozhong, Pan, Yiwen, Yang, Hao, Ye, Wenrui, Xu, Keli, Li, Zhijian, Zhang, Shubing
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7182462/
https://ncbi.nlm.nih.gov/pubmed/32368142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S250171
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky